GALVUS (VILDAGLIPTIN). NĀ PAPA MAʻI DIABETES GALVUS MET - VILDAGLIPTIN ME METFORMIN

Send

ʻO Galvus kahi lāʻau lapaʻau no ka maʻi maʻi, ka mea ikaika o ka vildagliptin, mai ka pūʻulu o DPP-4 inhibitors. Ua hoʻopaʻa inoa ʻia nā papa maʻi diabetes Galvus mai Lūkini mai 2009. Hana ʻia lākou e Novartis Pharma (Switzerland).

Nā papa papa Galvus no ka maʻi maʻi mai ka hui o nā mea paʻa o DPP-4 - ka waiwai ikaikaʻo Vildagliptin

Ua hoʻopaʻa inoa ʻia ʻo Galvus no ka mālama ʻana i nā maʻi me ka maʻi maʻi type 2. Hiki ke hoʻohana ʻia e like me ka lāʻau lapaʻau wale nō, a ʻo kona hopena e hoʻopiha i ka hopena o ka meaʻai a me ka hoʻoikaika. Hiki nō ke hoʻohana ʻia nā paila maʻi Galvus e hui pū me:

metformin (siofor, glucophage);
hana ʻia (sulfonylurea) (mai hana kēia!);
thiazolinediones;
insulin

E hoʻokuʻu i ke ʻano

Kauka lāʻau lapaʻau Galvus (vildagliptin) - papa 50 mg.

Nā papaʻu papa Galvus

ʻO ka maʻi maʻamau o Galvus e like me ka monotherapy a i hui pū paha me metformin, thiazolinediones a i ole insulin - 2 mau manawa i kahi lā, 50 mg, kakahiaka a me ke ahiahi, me ka manaʻo o ka komo ʻana o ka meaʻai. Inā hoʻoholo ʻia ka mea maʻi i kahi mahele o 1 papa o ke 50 mg i ka lā, a laila e lawe i ke kakahiaka.

Vildagliptin - ka hana ikaika o ka lāʻau no ka maʻi Galvus - ua hoʻopili ʻia e nā palaka, akā ma ke ʻano o nā metabolite hana ʻole. No laila, i ka hoʻomaka mua o ka pilikia ʻole, ʻaʻole pono ke loli ka nui o ka lāʻau.

Inā he mau hewa hōʻeha o ka hana o ka ate (ALT a i ʻole nā huina o AST 2,5 mau manawa ma mua o ka palena palena o ka maʻamau), a laila pono ke kuhikuhi ʻia ʻo Galvus me ka akahele. Inā ulu ka mea maʻi i ka jaundice a i ʻole nā hoʻopiʻi kūpaʻa ʻē aʻe, e hoʻopau koke i ka vildagliptin therapy.

No nā maʻi maʻi i ka makahiki 65 a keu aku - ʻaʻole i loli ka nui o Galvus inā ʻaʻohe concomitant pathology. ʻAʻohe ʻikepili e pili ana i ka hoʻohana ʻana i kēia lāʻau lapaʻau maʻi i nā keiki a me nā ʻōpio i lalo o 18 makahiki o kona mau makahiki. No laila, ʻaʻole ia e kuhikuhi ʻia e kuhikuhi i nā mea maʻi i kēia ʻano makahiki.

Hoʻohālikelike i ka hopena o ka Sugar

ʻO ka hopena haʻahaʻa hilo o ka vildagliptin i hoʻopaʻa ʻia ma kahi hui o 354 nā mea maʻi. Ua hoʻohuli ʻia ka monotherapy galvus i loko o nā hebedoma 24 i alakaʻi i ka nui o ke kahe koko i loko o kēlā mau maʻi i loaʻa ʻole iā lākou i ka maʻi o ka maʻi 2. ʻO kā lākou helu hemoglobin glycated i hōʻemi e 0.4-0.8%, a ma ka hui plasebo - ma ka 0.1%.

Eia kekahi hoʻohālike hoʻohālikelike i nā hopena o vildagliptin a me ka metformin, ka lāʻau lapaʻau maʻi kaulana loa (siofor, glucophage). Ke komo pū nei kēia haʻawina i nā mea maʻi i maʻi hou i nā maʻi maʻi type 2, a ʻaʻole i mālama ʻia ma mua.

Ka mea i hoʻohuli ʻia ka galvus i nā hōʻailona hoʻokō he nui ʻole i ka moʻo me ka metformin. Ma hope o 52 mau pule (1 makahiki o ka mālama ʻana) i nā mea maʻi e lawe ana i ka galvus, hoʻemi ka nui o ka hemoglobin glycated e ka awelika o 1.0%. I ka hui metformin, hoʻemi ʻia e 1,4%. Ma hope o 2 mau makahiki, ua like mau nā helu.

Ma hope o 52 mau pule o ka lawe ʻana i nā papa, ka mea i huli ka nui o ke kaumaha o ke kino i nā mea maʻi i nā hui o vildagliptin a me ka metformin like like like.

ʻIke ʻia ka Galvus e nā mea maʻi ma mua o ka metformin (Siofor). Hoʻokomo pinepine nā hopena ʻaoʻao mai ka gastrointestinal tract i nā manawa pinepine ʻole. No laila, ua hōʻoia ka hoʻokele hoʻokūkū kūʻokoʻa o kēia mau lā no ka mālama ʻana i ka maʻi type 2 no ka mea e hoʻomaka ai ka hana me ka galvus, me ka metformin.

ʻO Galvus Met: vildagliptin + hui metformin

ʻO Galvus Met kahi lāʻau lapaʻau hoʻohui, 1 papa o kēlā me kēia vildagliptin i loko o kahi waihona o 50 mg a me ka metformin i nā inaluna o 500, 850 a i ʻole 1000 mg. Kakau ʻia ma Rūsia ma Malaki 2009. Hoʻomaopopo ʻia e kuhikuhi i nā mea maʻi 1 papa 2 mau manawa i ka lā.

ʻO Galvus Met kahi lāʻau lapaʻau hoʻohui no nā maʻi maʻi type 2. Aia ia ka vildagliptin a me metformin. ʻElua mau mea hana i hoʻokahi papa - kūpono ia e hoʻohana a maikaʻi.

ʻO ka hui pū ʻana o ka vildagliptin a me ke metformin e ʻike ʻia i kūpono no ka mālama ʻana i nā maʻi maʻi type 2 i nā maʻi maʻi i lawe ʻole i ka metformin wale nō. Loaʻa i kona pono:

hoʻonui ka hopena o ka hoʻohaʻahaʻa i ke kiʻekiʻe o ka glucose koko, e hoʻohālikelike me ka monotherapy me kekahi o nā lāʻau lapaʻau;
mālama ʻia ke koena o nā hana beta ma ka hana ʻana o ka insulin;
ʻaʻole i hoʻonui ʻia ke kino o ke kino i nā mea maʻi;
ka hopena o ka hypoglycemia, me ke kaumaha nui, ʻaʻole i hoʻonui;
i ka nui o nā hopena ʻokoʻa o ka metformin mai ka gastrointestinal tract - e noho ma ka pae like, ʻaʻole e hoʻonui.

Ua hōʻike ʻia nā haʻawina e ʻoi aku ka maikaʻi o ka lawe ʻana iā Galvus Met e like me ka lawe ʻana i ʻelua papa ʻokoʻa me ka metformin a me vildagliptin. Akā inā pono ʻoe e lawe i hoʻokahi papa hoʻokahi, no laila e maʻalahi a maʻalahi ka lāʻau e mālama ai. No ka mea, ʻoi aku ka liʻiliʻi e poina a hoʻoweliweli paha ka mea maʻi i kekahi mea.

Nānā i kahi noiʻi - hoʻohālikelike i ka hoʻomohala ʻana o ke maʻi maʻi me Galvus Met me kahi hana maʻamau: metformin + sulfonylureas. Ua kau ʻia ʻo Sulfonylureas i nā mea maʻi me ka maʻi maʻi i loaʻa iā Metformin wale nō e lawa ʻole.

ʻO ka laulā nui ka ʻike nui. ʻOi aku paha ma kahi o 1300 nā mea maʻi ma nā pūʻulu ʻelua i komo i loko o ia mea. Duration - 1 makahiki. Ka mea i loko o nā mea maʻi e lawe vildagliptin (50 mg 2 mau manawa i ka lā) me ka metformin, hoʻemi ka nui o ke kahe koko a me nā poʻe e lawe ana i ka glimepiride (6 mg 1 manawa i kēlā me kēia lā).

ʻAʻohe hopena nui i loaʻa i nā hopena no ka hoʻohaʻahaʻa i ke kō koko. Ma ka manawa like nei, ʻike ka poʻe maʻi ma ka hui ʻo Galvus Met drug hypoglycemia 10 mau manawa ma mua o ka poʻe i mālama ʻia me glimepiride me nā metformin. ʻAʻohe mau hihia o ka hypoglycemia koʻikoʻi i nā maʻi e lawe ana iā Galvus Met no ka makahiki holoʻokoʻa.

Pehea e hoʻohana ʻia ai nā paila maʻi Galvus me Insulin

ʻO Galvus ka lāʻau lapaʻau mua mua i ka hui DPP-4 inhibitor, i kākau inoa ʻia no ka hoʻohana like ʻana me insulin. Ma ke kānāwai, ua kuhikuhi ʻia inā ʻaʻole hiki ke hoʻokele maikaʻi i ka maʻi maʻamau i ka maʻi maʻamau me ka wai basal wale nō, ʻo ia ka "lohi" insulin.

Ua loiloi kahi noiʻi 2007 i ka maikaʻi a me ka palekana o ka hoʻohui ʻana i ka galvus (50 mg 2 mau manawa i ka lā) e kū'ē i ka placebo. Ua komo ka poʻe maʻi i noho i ka kiʻekiʻe o ka hemoglobin glycated (7.5-111%) i ka hōʻemi ʻana i ka "average" insulin me ka pale ʻana o Hagedorn neʻe (NPH) i ka nui o nā mea he 30 mau lā / lā.

Ua loaʻa i nā mea maʻi 144 ka galvus me nā inikini insulin, 152 nā mea maʻi me ka maʻi diabetes type 2 i loaʻa i ka placebo ma ke ala o nā inikini insulin. I ka hui vildagliptin, ʻo ka palena iki o ka hemoglobin glycated i hoʻohaʻahaʻa loa e ka 0.5%. I ka hui placebo, ma o 0.2%. I ka poʻe maʻi i ʻoi aku ma mua o 65 mau makahiki, ʻoi aku ka maikaʻi o nā hōʻailona. ʻO ka hōʻemi o 0.7% ma ka ʻaoʻao o ke galvus a me 0.1% ma muli o ka lawe ʻana i kahi placebo.

Ma hope o ka hoʻohui ʻana i ka galvus i ka insulin, ua hoʻohaʻahaʻa nui ka nui o ka hypoglycemia, ke hoʻohālikelike ʻia me ka maʻi maʻi maʻi maʻi, ka hōʻemi ʻana o ka "average" NPH-insulin. I ka hui vildagliptin, ʻo ka huina o nā episodere o ka hypoglycemia he 113, i ka hui plasebo - 185. Eia kekahi, ʻaʻole i hoʻopaʻa ʻia kahi hihia o ka hypoglycemia koʻikoʻi i ka wā e pili ana i ka lāʻau vildagliptin. Aia he 6 ia mau hanana i ka hui plana.

Nā hopena hopena

Ma keʻano laulā, ʻo ka galvus he lāʻau palekana loa. Hōʻoia nā haʻawina ʻo ka lāʻau no ke maʻi type 2 me kēia lāʻau lapaʻau ʻaʻole e hoʻonui i ka maʻi o ka maʻi cardiovascular, pilikia ʻili, a i ʻole nā pale kino. ʻO ka lawe ʻana i ka vildagliptin (ʻo ka mea kanu ikaika i nā papa galvus) ʻaʻole i hoʻonui i ka paona kino.

Hoʻohālikelike ʻia me nā kuʻuna hoʻohaʻahaʻa i ka wai koko kuʻuna, a me ka placebo, galvus ʻaʻole i hoʻonui i ka maʻi o ka pancreatitis. ʻO ka hapa nui o nā hopena ʻaoʻao he ʻoluʻolu a mālie. Loaʻa pinepine ʻia: